Analysts Raise Gilead Sciences Price Targets After Q3 Results
UBS raised its target to $195 from $175 and maintained a Buy rating; Needham increased its target to $200 from $170. RBC raised its target to $131 from $126, while Leerink Partners adjusted its target to $145 from $129.